Evidence map›Paper›PMID 32549781›Full record

ArticleJournal of medical biochemistry2020

Urinary nephrin is earlier, more sensitive and specific marker of diabetic nephropathy than microalbuminuria.

Irena Kostovska, Katerina Tosheska-Trajkovska, Sonja Topuzovska, Svetlana Cekovska, Goce Spasovski, Ognen Kostovski, Danica Labudovic

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medical biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05298163 (Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients), which is not on this map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05298163 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Effects of Calcitriol on Podocytes in Diabetic Kidney Disease Patients: Assessment of Urine Podocin, Urine Nephrin, Urine Interleukin-6, Urine KIM-1, Plasma Renin, and Albuminuria

TypeinterventionalSponsorIndonesia UniversityRan2022 to 2022Enrolled120ConditionsDiabetic Kidney DiseaseArmsCalcitriol capsules, Placebo
3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Protective Effects ofBiomedicines · 2025
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Urinary podocyte markers in diabetic kidney disease.Kidney research and clinical practice · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Irena KostovskaMedical Faculty, Department of Medical and Experimental Biochemistry, Skopje, R. Macedonia.
Katerina Tosheska-TrajkovskaMedical Faculty, Department of Medical and Experimental Biochemistry, Skopje, R. Macedonia.
Sonja TopuzovskaMedical Faculty, Department of Medical and Experimental Biochemistry, Skopje, R. Macedonia.
Svetlana CekovskaMedical Faculty, Department of Medical and Experimental Biochemistry, Skopje, R. Macedonia.
Goce SpasovskiMedical Faculty, University Department of Nephrology, Skopje, R. Macedonia.
Ognen KostovskiMedical Faculty, University Clinic of Abdominal Surgery, Skopje, R. Macedonia.
Danica LabudovicMedical Faculty, Department of Medical and Experimental Biochemistry, Skopje, R. Macedonia.
Saints Cyril and Methodius University of Skopje · MKUniversity Clinic of Traumatology · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDiabetic nephropathy (DN) is a leading cause of end-stage renal disease. Progressive damage and decline in the number of podocytes often occur in the early stages of DN. Thus, nephrin as a podocyte-specific protein may be regarded as a potential biomarker of early detection of DN. The aim of this study is to determine whether urinary nephrin is an earlier marker in DN than microalbuminuria and to test the significance of urinary nephrin as a marker for early detection of DN.

methodsOur cross-sectional study included 90 patients with type 2 diabetes mellitus (T2DM), 30 patients with diagnosed DN and 60 patients without diagnosed DN. As a control group, we used 30 healthy subjects. All patients with T2DM were classified into three subgroups according to urinary microalbumin/creatinine ratio (UMCR): normoalbuminuric, microalbuminuric and macroalbuminuric patients. Nephrin in urine was measured by immunoenzyme assay, microalbumin with turbidimetric and creatinine with the photometric method. In blood sera, we measured a few standard biochemical parameters.

resultsNephrinuria was found to be present in 100% of patients with T2DM and macroalbuminuria, in 88% with microalbuminuria, as well as 82% of patients with T2DM and normoalbuminuria. A concentration of urinary nephrin was significantly increased in all groups of subjects with T2DM compared to the control group (p<0.05). Nephrinuria correlated statistically negative with eGFR (r=-0.54). ROC analysis showed that nephrin has a total predicted probability of 96% in patients with DN.

conclusionsUrinary nephrin is earlier, more specific and sensitive marker than microalbumin in early detection of DN.

Indexed as

diabetic nephropathymicroalbuminnephrin

Identifiers

PMID32549781
PMCPMC7282240
OpenAlexW2948348134

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.